Season's Savings | ₹5/mo for 3 months
₹199/month after first 3 months. Renews automatically. Terms apply.
Amgen Q3 2026 Earnings Analysis
Failed to add items
Sorry, we are unable to add the item because your shopping basket is already at capacity.
Add to cart failed.
Please try again later
Add to wishlist failed.
Please try again later
Remove from wishlist failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
Written by:
About this listen
──────────
**ALEX:** Welcome to Beta Finch, your AI-powered earnings breakdown! I'm Alex.
**JORDAN:** And I'm Jordan. Today we're digging into Amgen's third quarter 2026 results — and honestly, this one's packed with pipeline news.
**ALEX:** It really is. But before we get into it, the standard note: this podcast is AI-generated content for educational and entertainment purposes only. Nothing we discuss should be considered investment advice. Always do your own research and consult a qualified financial advisor before making any investment decisions.
**JORDAN:** Good, let's get into the numbers.
**ALEX:** Amgen posted $10.4 billion in total revenue for Q3, up 8% year-over-year. And the headline stat from management: six key growth drivers — Repatha, EVENITY, TEZSPIRE, UPLIZNA, BLINCYTO, and IMDELLTRA — now make up over 70% of product sales, and together they grew 27%.
**JORDAN:** That's a meaningful shift in the revenue mix. It tells you Amgen isn't just leaning on legacy blockbusters anymore — it's a portfolio actually built around newer, faster-growing medicines. Seventeen products posted double-digit growth, and seventeen are now annualizing above a billion dollars each.
**ALEX:** On profitability, non-GAAP operating margin came in at 47%, free cash flow was $3.7 billion, and R&D spending jumped 11% — they're clearly reinvesting aggressively.
**JORDAN:** And the market liked it — shares were up over 3% on the print. Amgen also raised full-year guidance: revenue now expected between $38.9 and $39.7 billion, and non-GAAP EPS between $22.90 and $23.70. That's a confident move with just one quarter left in the year.
**ALEX:** Let's talk individual products, because there's a lot here. Repatha did $1.1 billion, up 37%, riding new cardiovascular outcomes data and updated treatment guidelines. EVENITY grew 39% to $751 million. TEZSPIRE was up 43% to $538 million.
**JORDAN:** And rare disease was a real standout — UPLIZNA sales were up 191% to $451 million. That's not a typo. Strong uptake in myasthenia gravis and really encouraging durability data in IgG4-related disease.
**ALEX:** Now let's get to what I think was the big story of the call — IMDELLTRA in small cell lung cancer.
**JORDAN:** Yeah, this is the one that had analysts buzzing. Sales more than doubled year-over-year to $406 million, but the real news was the Phase III DeLLphi-305 data presented at ESMO. In first-line maintenance, IMDELLTRA plus Imfinzi showed a median overall survival of 21.1 months versus 12.7 months for Imfinzi alone.
**ALEX:** Management described getting a standing ovation when that data was presented in Madrid. That's not something you hear often on an oncology readout.
**JORDAN:** And it's not just the efficacy — the monitoring burden is dropping too. Original label required 22 to 24 hours of monitoring for the first doses; that's now down to 6 to 8 hours, and in this newer study design, monitoring was as low as 1 to 2 hours. That could open the door to community oncology clinics actually administering this, not just big academic centers.
**ALEX:** On the call, Murdo Gordon, the commercial chief, called it a potential "cornerstone therapy" for small cell lung cancer — and noted the first-line maintenance opportunity alone could address roughly 23,000 patients in the U.S.
**JORDAN:** Beyond IMDELLTRA, they also had positive Phase III results for TEZSPIRE in eosinophilic esophagitis and for dazodalibep in Sjögren's disease — a condition with zero approved disease-modifying therapies today. Three positive Phase III readouts in one quarter is a strong batting average for an R&D org.
**ALEX:** There was good Q&A color too. On MariTide, Amgen's obesity candidate, CFO Thomas Dittrich — in his first call as CFO — confirmed they're sticking with about $2.6 billion in CapEx this year, partly to prepare manufacturing for a potential MariTide launch.
**JORDAN:** And when asked about tolerability,
This episode includes AI-generated content.
adbl_web_anon_alc_button_suppression_t1
No reviews yet